In 1987 a small group of endocrinologists showed that a fragment of a gut hormone made the pancreas release insulin, but only when blood sugar was high. In 1992 a researcher at the Bronx VA found a longer lasting version of the same molecule in the venom of the Gila monster. Thirteen years later it became a diabetes drug that nobody outside endocrinology had heard of.
The family now has outcome trials in diabetes, obesity, heart disease, heart failure, kidney disease, fatty liver and sleep apnea, and a symptom trial in arthritic knees. It also has a large and well funded failure in Alzheimer's disease, which is part of the story.
This page treats the drug family as the patient. The timeline is its chart, one dot per study, from the first insulin experiment to this year's readouts. Below that is a ledger for each use (how it works, what has been shown, what is still open, and how good the evidence is), then the side effects, then the practical problems of cost and tolerance. It will be updated as results arrive.
Disclosure. I am a kidney doctor. I treat patients with the diseases these drugs treat, which is a conflict of a kind, and I would like more of my patients to be able to take them. I do not make money from these drugs.
How this was built. Trial results come from the primary publications and regulatory documents linked below. The kidney stage table started from an OpenEvidence literature summary and was checked against the papers. Some 2025 and 2026 results are company announcements not yet peer reviewed. They are marked as such and may move when published. Claude drafted the page from my reading.
| Year | Drug | Use | Evidence | Finding | Source |
|---|
GLP-1 tells the pancreas to release insulin, but only when glucose is elevated, which is why these drugs rarely cause low blood sugar on their own (rarely is not never, especially with poor intake or frailty). It also suppresses glucagon and slows the stomach. GIP (the second hormone in tirzepatide) adds its own insulin effect. Whether it also improves tolerability is debated.
A1c falls by roughly 1 to 2 points. In a head to head trial tirzepatide lowered A1c more than semaglutide 1 mg (2.3 against 1.9 points). The retatrutide topline reports up to 2.0 points. Low blood sugar is mainly a risk when combined with insulin or sulfonylureas.
Who responds and who does not, and whether glucose control holds over decades rather than years.
Dozens of randomized trials across every drug in the class. The best established use.
Supporting studies on PubMed (1)
Mostly through weight loss and better insulin sensitivity, which takes strain off the insulin producing beta cells.
Three year liraglutide data (SCALE) cut new diabetes from about 6% to 2%. In SURMOUNT-1, tirzepatide cut progression by 94% over 176 weeks in 1,032 people with prediabetes. Seventeen weeks after stopping, 2.4% of the tirzepatide group had diabetes against 13.7% on placebo, so the effect starts fading once the drug stops.
Whether this is prevention or postponement. Nobody has followed people for years after stopping. Cost effectiveness for a population this large is unresolved.
Randomized, but diabetes onset was a secondary endpoint in trials built around weight.
Supporting studies on PubMed (3)
- 2024SURMOUNT-1, 3 years: tirzepatide in prediabetes PubMed
- 2024STEP 10: semaglutide in prediabetes PubMed
- 2017SCALE prediabetes: liraglutide 3 mg, 3 years PubMed
Receptors in the hypothalamus and brainstem reduce hunger and the reward value of food. Slower stomach emptying adds fullness. Glucagon (the third hormone in retatrutide) is thought to raise energy expenditure, which is plausible but not yet measured well in people.
Each generation has raised the ceiling. About 8% with liraglutide (2015), 15% with semaglutide (2021), 21% with tirzepatide (2022), and 28% at 80 weeks with retatrutide (2026 topline). Orforglipron, the first small molecule pill, gave 12% in those who stayed on it and 11% by intention to treat (2025). Weight returns after stopping. In the STEP 1 extension about two thirds of the loss came back within a year of stopping. Real practice looks different because few people simply stop. In 20,486 Cleveland Clinic patients followed for two years after at least three months on semaglutide or tirzepatide, weight loss was 10.9% for those who stayed on their drug, 16% for those who switched between the two, 8.2% for those who moved to another obesity drug, 28.2% after bariatric surgery (chosen by about 1%), and 4% for those who stopped (observational, eClinicalMedicine 2026).
Whether treatment must be lifelong, what the right maintenance dose is, and why real world weight loss runs well below trial results. Who will respond is hard to predict at the start; baseline traits explain little. Early response may be the better guide. In a UK digital service, weight lost in the first three months predicted one year response (about 9% at three months on semaglutide 2.4 mg, or 10% on tirzepatide, foretold 15% at a year in roughly 5 of 6 cases), though this comes from company authored conference abstracts.
Large placebo controlled trials for every agent. Long term data beyond three to four years are sparse.
Supporting studies on PubMed (12)
- 2026After the GLP-1: which exit strategy holds weight (target trial emulation, 20,486 patients) Gasoyan H et al. eClinicalMedicine 2026 not yet indexed; Medscape report
- 2026Bariatric surgery as a rescue strategy after semaglutide or tirzepatide Aminian A et al. Ann Surg 2026 PubMed
- 2026Early weight loss predicts one year response Johnson H et al. Obesity Week 2026 abstracts conference abstract, company authors
- 2026Lean mass is not all muscle: liver shrinks faster, strength maintained Langer HT et al. Cell Rep Med 2026 PubMed
- 2024Semaglutide and bone density in adults at increased fracture risk Hansen MS et al. eClinicalMedicine 2024 PubMed
- 2024Bone density after liraglutide, exercise or both Jensen SBK et al. JAMA Netw Open 2024 PubMed
- 2026TRIUMPH-1: retatrutide (triple agonist) topline or news report
- 2025ATTAIN-1: orforglipron pill PubMed
- 2022STEP 1 extension: weight regain after stopping semaglutide Wilding JPH et al. Diabetes Obes Metab 2022 PubMed
- 2022SURMOUNT-1: tirzepatide PubMed
- 2021STEP 1: semaglutide 2.4 mg PubMed
- 2015SCALE: liraglutide 3 mg PubMed
Not fully through weight. In SELECT the benefit appeared early, before most of the weight was lost, and in one mediation analysis about a third of it tracked waist reduction. Mediation analyses cannot prove mechanism, but the remainder is likely lower blood pressure, better lipids, less inflammation and direct effects on blood vessels and plaque.
Major cardiovascular events fall by roughly 12 to 26% in people with diabetes (LEADER, SUSTAIN-6, REWIND, SOUL) and by 20% in people with obesity but no diabetes (SELECT). Not every member of the class worked; exenatide once weekly missed significance in EXSCEL. Tirzepatide was noninferior to dulaglutide but did not prove superior on the primary endpoint; deaths were 16% lower, a secondary finding. Semaglutide also improved walking distance in peripheral artery disease (STRIDE).
Whether the dual and triple agonists protect the heart more than GLP-1 alone. Whether benefit persists after stopping. Retatrutide's cardiovascular trial reads out later.
Multiple large outcome trials, mostly industry funded, consistent in direction across agents.
Supporting studies on PubMed (9)
- 2025SURPASS-CVOT: tirzepatide against dulaglutide PubMed
- 2025SELECT: benefit by baseline and change in adiposity Deanfield J et al. Lancet 2025;406:2257 PubMed
- 2025STRIDE: peripheral artery disease PubMed
- 2025SOUL: oral semaglutide PubMed
- 2023SELECT: semaglutide, obesity without diabetes PubMed
- 2019REWIND: dulaglutide PubMed
- 2017EXSCEL: exenatide weekly PubMed
- 2016SUSTAIN-6: semaglutide PubMed
- 2016LEADER: liraglutide PubMed
In heart failure with preserved ejection fraction, the stiff heart common in obesity, losing visceral and pericardial fat lowers filling pressures. Less inflammation and lower blood volume probably help.
STEP-HFpEF improved symptoms and walking distance. SUMMIT (tirzepatide, 731 people) cut cardiovascular death or worsening heart failure by 38%, driven mostly by fewer heart failure events.
SUMMIT was small, with few events. In heart failure with reduced ejection fraction there is no evidence of benefit, and an early liraglutide trial (FIGHT) was neutral.
Randomized, consistent, but small compared with the heart attack and stroke trials.
Supporting studies on PubMed (3)
- 2024SUMMIT: tirzepatide in HFpEF PubMed
- 2023STEP-HFpEF PubMed
- 2016FIGHT: liraglutide in reduced ejection fraction heart failure (neutral) Margulies KB et al. JAMA 2016 PubMed
The kidney benefit is partly glucose, weight and blood pressure, and partly direct. GLP-1 causes the proximal tubule to excrete more sodium, lowers albumin leakage, and reduces kidney fat. REMODEL (Nature Medicine, October 2026) scanned 106 people and biopsied 33 before and after a year of semaglutide. Its three MRI primary endpoints (oxygenation, perfusion, inflammation) did not move. Among secondary findings, renal artery resistance fell and an MRI marker of fibrosis held steady. Albuminuria fell 40%, an exploratory result. On biopsy, the cells lining the glomerular capillaries switched off genes for inflammation and fibrosis, with fewer immune cells nearby. Novo Nordisk funded the trial. That is the mechanism story so far, and it is not finished.
FLOW, the first trial designed around kidney outcomes, enrolled 3,533 people with type 2 diabetes and albuminuric CKD (eGFR 25 to 75). Semaglutide cut the primary composite (kidney failure, a sustained 50% drop in eGFR, or kidney or cardiovascular death) by 24%, cardiovascular events by 18% and death by 20%, and earned a kidney indication in January 2025. Only about 16% of participants took an SGLT2 inhibitor at baseline. Earlier heart trials showed kidney benefit mostly as less albuminuria. In SELECT, people without diabetes also had fewer kidney events (HR 0.78), a secondary analysis that carries less weight than FLOW.
Benefit in CKD without diabetes (SMART halved albuminuria in 101 people, with no outcome trial yet). Added benefit on top of SGLT2 inhibitors and finerenone. Starting treatment below an eGFR of 25, where there are essentially no randomized data. See the table below.
| Stage | Evidence | What is known | What is open |
|---|---|---|---|
| eGFR 45 and up, with albuminuria | Strong | Heart outcome trials (LEADER, SUSTAIN-6, REWIND) reduce the kidney composite, mostly through less albuminuria. FLOW required heavy albuminuria (UACR over 300) at eGFR 50 to 75. Without diabetes, SMART cut albuminuria 52% and SELECT kidney events 22%. | Hard outcomes in people without albuminuria. Outcome trials in CKD without diabetes. Benefit on top of SGLT2i and finerenone. |
| G3b (eGFR 30 to 44) | Strong | FLOW included eGFR 25 to 49 with UACR over 100. A meta-analysis of 17,996 people with eGFR under 60 found fewer kidney events (OR 0.85), less 50% eGFR decline (OR 0.72) and lower death (OR 0.77). AWARD-7 showed slower eGFR decline with dulaglutide than insulin. | The FLOW subgroup already on SGLT2i was small and inconclusive. Tirzepatide and newer agents. People without albuminuria. |
| G4 (eGFR 15 to 29) | Moderate at 25 to 29, thin below | FLOW enrolled down to eGFR 25, with few participants at that level. AWARD-7 went down to eGFR 15, with good glucose control, slower decline and about half the hypoglycemia of insulin. Observational data show less progression to dialysis and lower death than with DPP-4 inhibitors. Below eGFR 25 the evidence is surrogate and observational. | No randomized starts below eGFR 25. Whether heart benefit holds. Malnutrition and muscle loss, since creatinine based eGFR also shifts as muscle is lost. |
| G5, not on dialysis | Thin | Semaglutide, liraglutide and dulaglutide lower glucose without dose adjustment and carry little intrinsic hypoglycemia risk. Exenatide is not recommended at this level. No dose adjustment is a pharmacokinetic fact, not proof of benefit. | Essentially no randomized data. Effect on time to dialysis, uremic nausea and nutrition. Effect on transplant candidacy. |
| Dialysis | Observational | A meta-analysis of 19 small studies: about 7 kg weight loss and 0.75 point A1c drop at a year (A1c is unreliable on dialysis), GI side effects in 39%, 9% stopped. A national cohort of 151,649 linked use with 23% lower mortality and 66% higher odds of transplant waitlisting, an association open to selection of healthier, better supported patients. | No outcome trials; the authors call the data hypothesis generating. Hemodialysis against peritoneal dialysis. Protein energy wasting, gastroparesis and aspiration. Bone: the fracture data so far exclude dialysis and advanced CKD. Weight loss as a bridge to transplant listing. |
| Kidney transplant | Observational | A meta-analysis of 17 studies and 54,680 recipients found lower death and cardiovascular events, with stable or slightly better graft function over two years. No clear rejection signal, and no consistent change in tacrolimus levels reported, though troughs deserve watching during dose increases and vomiting. | All retrospective, with selection bias and short follow up. Long term graft survival. A retinopathy signal in one cohort. Randomized trials are under way. |
Supporting studies on PubMed (14)
- 2026REMODEL: looking for how semaglutide protects the kidney PubMed
- 2026Transplant recipients: meta-analysis PubMed Central
- 2026Incretin medications: metabolic, cardiovascular and renal benefits (review) Lancet 2026 PubMed
- 2025Dialysis: meta-analysis and national cohort PubMed
- 2025ADA Standards of Care 2026, section 11: CKD Diabetes Care 2026 PubMed
- 2025Meta-analysis, eGFR under 60 PubMed
- 2025GLP-1 RAs in kidney transplant recipients with diabetes (cohort) Lancet Diabetes Endocrinol 2025 PubMed
- 2024SELECT kidney outcomes PubMed
- 2024SMART: CKD without diabetes PubMed
- 2024FLOW: semaglutide in diabetic CKD PubMed
- 2023GLP-1 RAs in advanced diabetic kidney disease Cardiovasc Diabetol 2023 PubMed
- 2022KDIGO 2022 guideline: diabetes management in CKD Kidney Int 2022 PubMed
- 2018AWARD-7: dulaglutide in CKD stages 3 to 4 PubMed
- 2017LEADER kidney outcomes PubMed
Mostly by removing fat from the liver through weight loss and better insulin sensitivity. Hepatocytes have few GLP-1 receptors, so a direct effect is unlikely.
In ESSENCE, 63% on semaglutide had resolution of steatohepatitis against 34% on placebo, and 37% had less fibrosis against 22%. The FDA granted accelerated approval in August 2025.
Whether better biopsies mean less cirrhosis, cancer and transplant. Part two of ESSENCE reports in 2029.
One large randomized trial on a histology surrogate. Clinical outcomes pending.
Supporting studies on PubMed (1)
- 2025ESSENCE: semaglutide in MASH PubMed
Less fat around the airway and tongue means less collapse during sleep.
In SURMOUNT-OSA, tirzepatide reduced apnea events by about 25 to 29 an hour against about 5 with placebo, and won approval in December 2024. The retatrutide topline reports up to 36 fewer events an hour.
Whether fewer events translate into fewer heart attacks and strokes, and what happens to apnea after stopping.
Randomized trials on a validated measure, with and without CPAP.
Supporting studies on PubMed (1)
- 2024SURMOUNT-OSA: tirzepatide PubMed
Less load on the joint is the obvious answer. The interesting one is inflammation. C-reactive protein falls in nearly every large trial, and mouse work from the Drucker lab showed that GLP-1 receptors in the brain can switch off systemic inflammation. Whether that matters in human knees is unknown.
In STEP 9, semaglutide cut knee pain scores by 41.7 points against 27.5 with placebo. In TRIUMPH-4 (topline), retatrutide cut pain by 4.5 points against 2.4, with a notably large placebo response.
Patients on drug also lost far more weight, so the trials cannot separate weight from anything else. No evidence yet of cartilage preservation. Psoriasis, inflammatory bowel disease and other inflammatory conditions rest on observational data.
Randomized symptom trials. Mechanism and weight independence remain hypotheses.
Supporting studies on PubMed (3)
- 2025TRIUMPH-4: retatrutide in knee osteoarthritis topline or news report
- 2024STEP 9: knee osteoarthritis PubMed
- 2024Brain GLP-1 receptors switch off inflammation (mice) PubMed
GLP-1 receptors in the brain, less inflammation, and better vascular health might slow neurodegeneration.
Health record studies suggested 40 to 70% lower dementia risk. EVOKE and EVOKE+ randomized 3,808 people with early Alzheimer's to oral semaglutide or placebo for two years. Some biomarkers moved. Disease progression did not.
This is the cleanest recent example of an observational signal that a proper trial did not confirm. People who get prescribed these drugs differ from people who do not, in ways no database fully captures. Every observational row on this page, including the dialysis and transplant rows, deserves the same caution.
Supporting studies on PubMed (2)
- 2025EVOKE and EVOKE+: Alzheimer's disease not indexed in PubMed
- 2024Health records: semaglutide and dementia PubMed
The same reward circuits that make food less appealing seem to blunt the pull of alcohol and possibly other drugs.
A small randomized trial of 48 people found semaglutide reduced alcohol consumed in a laboratory setting and heavy drinking days. Large health record studies point the same way.
Everything that a larger trial would answer. See the Alzheimer's card for why that matters.
One small trial plus observational data.
Supporting studies on PubMed (2)
- 2026GLP-1 drugs and worsening mental illness, including substance use (Swedish cohort) Taipale H et al. Lancet Psychiatry 2026 PubMed
- 2025Semaglutide in alcohol use disorder PubMed
| Effect | When noticed | Who and how often | Status |
|---|---|---|---|
| Nausea, vomiting, diarrhea, constipation | From the first trials | The most common reason to stop. GI events in 36% on dulaglutide and 43% on tirzepatide in SURPASS-CVOT; nausea in 42% on retatrutide 12 mg. Worst during dose increases and usually fades. | Expected. Slower titration helps. |
| Dehydration and acute kidney injury | Labeled since the early drugs | Vomiting, diarrhea and poor intake, especially in older or CKD patients on diuretics, RAAS blockers or SGLT2 inhibitors. | On the label. Hold the drug during sick days; check kidney function if GI losses are heavy. |
| Pregnancy and oral contraceptives | Labels from approval | Not for use in pregnancy; semaglutide needs about two months of washout. Tirzepatide can lower oral contraceptive levels during dose increases. | On the label. Use a backup or non oral method around tirzepatide dose changes. |
| Faster resting heart rate | Early trials | Rises by a few beats a minute, more with glucagon containing agonists. | Known. Clinical meaning unclear. |
| Pancreatitis | 2007 FDA alert | Rare. The large outcome trials show little or no excess. | On the label. Use caution, or another drug, after prior pancreatitis. |
| Thyroid C-cell tumors | 2010, in rodents | Seen in rodents. No confirmed human signal. | Boxed warning. Avoid with personal or family history of medullary thyroid cancer or MEN2. |
| Cancer in general | Long watched; meta-analysis December 2025 | Across 48 placebo controlled trials (94,245 people), GLP-1 drugs probably have little or no effect on thyroid, pancreatic, breast or kidney cancer (moderate certainty), and may have little effect on several others. The trials were short and not built to find cancer. Observational hints of fewer obesity related cancers are unproven. | Reassuring so far. Long latency harms are the ones surveillance catches last. |
| Gallbladder disease | Weight loss trials | More gallstones, partly from rapid weight loss, with a drug effect seen in randomized trials. | On the label. |
| Diabetic eye disease worsening | 2016 (SUSTAIN-6) | People with existing retinopathy whose A1c falls fast. Across 78 semaglutide trials (73,640 people), retinopathy overall was not increased (OR 1.04). | Overall risk not raised in trials; early worsening with rapid glucose drops remains the concern. Watch closely; a dedicated trial is under way. |
| Muscle and lean mass loss | 2021 body composition substudies | About 25 to 40% of weight lost is lean mass on DXA, which counts muscle, water, glycogen and organs together. A 2026 study (mice plus a small human trial) found the liver shrank faster than muscle as fat cleared from it, and people on GLP-1s lost a little absolute muscle while keeping their strength. Matters most in older, frail and dialysis patients. | Less alarming than the 40% headline, not settled. Protein and resistance exercise advised; long term function data lacking. |
| Bone density loss | 2024 randomized data | Hip and spine density fall with weight loss. In the only placebo controlled semaglutide bone trial (64 adults at raised fracture risk, 86% postmenopausal women), a year of treatment lowered total hip and spine density, raised a marker of bone breakdown and did not raise bone formation; the authors attribute this to the 6.8 kg weight loss. In a 195 person trial, liraglutide alone lowered hip and spine density more than exercise alone despite similar weight loss; liraglutide plus exercise kept bone density level with placebo. The fracture studies conflict. In 133,606 adults with type 2 diabetes, starting a GLP-1 was linked to 21% fewer fragility fractures over three years than starting a DPP-4 inhibitor (NNT 126), fading by year three; that study excluded CKD stages 4 and 5, dialysis and known osteoporosis. But in 46,177 Israeli adults 65 and older with diabetes, GLP-1 starters had 11% more fragility fractures than SGLT2 or DPP-4 starters, and in 66,420 people with obesity and no diabetes, fracture risk was higher on GLP-1s, most clearly in people over 67. A five year study of upper extremity fractures found no difference either way. None of these is randomized, and none speaks for dialysis patients. | Open. Exercise, protein, calcium and vitamin D; consider a DXA scan in people at fracture risk. |
| Aspiration during anesthesia | 2023 anesthesia guidance | Food can remain in a slowed stomach despite fasting, most during dose increases or with GI symptoms. Severe gastroparesis and bowel obstruction are on some labels. | Guidance now stratifies risk rather than holding every patient. |
| Compounded copies with added ingredients | 2024 to 2026 | People buying cash pay compounded semaglutide or tirzepatide from telehealth sites, clinics and med spas. In 2026 studies, 60% of online compounded products and 56% of clinic offerings came mixed with B vitamins, levocarnitine or glycine. These are sold as preventing side effects, with little evidence that they do, and the combinations have never been tested for safety. Some supplying pharmacies were not licensed for sterile compounding. The FDA had logged more than 1,700 adverse event reports tied to compounded semaglutide and tirzepatide by May 2026. | Unregulated; contents often unverifiable. Ask patients directly, because cash purchases rarely appear in medication histories. |
| Suicidal thoughts | Investigated 2023 | FDA meta-analysis of 91 trials and nearly 108,000 people found no increased risk. In a Swedish national cohort of 95,490 people with depression or anxiety, periods on semaglutide were linked to less worsening of mental illness (aHR 0.58) and GLP-1 drugs as a group to less self-harm (observational). Reports of flattened mood and of relapse in eating disorders remain anecdotal. | Cleared. FDA asked for warnings to be removed in January 2026. Ask about mental health and eating disorder history before prescribing. |
| Optic nerve stroke (NAION) | First reports 2024; EMA 2025; FDA November 2026 | Rare but real enough to label. Across 126 randomized trials the FDA counted 6.4 cases per 100,000 person years on GLP-1 drugs. In 102,361 veterans with diabetes, semaglutide starters had 2.3 times the NAION risk of SGLT2 inhibitor starters (123 against 67 per 100,000 person years). A meta-analysis of 78 semaglutide trials found higher odds with a very wide interval and too few cases to be definitive. One eye affected raises the risk to the other. | On November 9, 2026 the FDA required a NAION warning on every GLP-1 drug, including tirzepatide and orforglipron. Consider stopping if NAION occurs; report sudden vision loss at once. The EMA classes it as very rare (up to 1 in 10,000) with semaglutide. |
| Skin sensations and urinary infections | 2025 to 2026 (retatrutide) | Reported in retatrutide toplines, without full definitions or comparator rates. | Not established. Awaits full publication. |
Who stops, and why
- In trials, 4 to 13% stop because of side effects, depending on drug and dose. In practice many more stop. One year persistence on obesity doses rose from about a third (2021) to about 60% (2024).
- In one survey of people who quit, cost, side effects and lack of coverage each drove about a third of stops. Among people with diabetes, side effects were the leading reason.
- Little is known about predicting who will not tolerate the drugs. Early trouble is a warning sign; patients with an emergency visit or a serious GI event in their first 90 days were 1.8 times more likely to stop. The practical answers are slower dose increases, staying on a lower dose, smaller meals, or switching agents.
- For people who cannot tolerate the drugs or do not respond, surgery still works. In a Cleveland Clinic cohort, bariatric surgery after intolerance or inadequate response produced two year weight loss of roughly 14% to 36% depending on the operation, similar to patients who had never taken the drugs.
- In advanced kidney disease, where appetite and nutrition are already fragile, tolerance is the open question more than efficacy.
What it costs
- List prices ran roughly $1,000 to $1,350 a month before late 2025, and shortages from about 2022 into 2025 fed a market in compounded copies.
- The compounded market did not end with the shortages. In Nebraska's statewide prescription tracking data, compounded GLP-1s went from none in 2018 to 86% of compounded weight loss prescriptions in 2025, mostly self paid and often shipped from out of state. Many now come with added vitamin B12 or levocarnitine, which is partly how sellers argue a product is "personalized" rather than a copy.
- A November 2025 federal agreement set Medicare and Medicaid prices at $245 a month and cash prices starting around $350.
- A Medicare GLP-1 Bridge program began July 1, 2026, covering obesity treatment for eligible patients at $50 a month through 2027. Coverage for obesity alone had been barred by law.
- The new pills are cheaper. Orforglipron launched with cash prices of $149 to $349 a month.
- Value depends on price and support. A UK model found tirzepatide cost effective against usual care for BMI 40 and above (about £23,000 per quality adjusted life year, under the £35,000 NICE threshold), and better value with online behavioral support added. It was built and presented by the company selling that support.
- Commercial coverage remains uneven. For many patients, price is still the deciding side effect.
- Whether these are lifelong drugs. Weight and glucose benefits fade within months of stopping, though in practice switching drugs or having surgery holds weight far better than stopping outright. Whether heart, kidney and liver benefits fade too is unknown, and no trial has followed people on them for fifteen years.
- Whether the kidney benefit extends to people without albuminuria, to people without diabetes, and to people who already take SGLT2 inhibitors and finerenone.
- Whether anything holds below an eGFR of 25, on dialysis, or after transplant, where all the evidence is observational.
- Whether the loss of lean mass and bone density translates into falls, fractures or disability over years, especially in older women, frail patients and people on dialysis. The fracture data in diabetes are reassuring; in people without diabetes they point the other way.
- Whether the dual and triple agonists protect organs better than GLP-1 alone, or simply cause more weight loss.
- Whether any of the inflammation story is independent of weight in humans.
- What is actually in compounded products, and whether added ingredients change their safety. Cash pay use is largely invisible to insurance claims and medication records, so it is also invisible to most safety surveillance.
- Rare harms with long latency, which surveillance catches last.
A hormone found in a lab dish and a lizard's venom now has outcome trials in the heart, the kidney, the liver and the airway. Each new trial has added an organ. The evidence thins exactly where kidney patients are sickest, and the bill is still the side effect most patients notice first.
Sources
Discovery: Mojsov S, Weir GC, Habener JF. Insulinotropin: GLP-1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release. J Clin Invest 1987;79:616. PubMed. Eng J et al. Isolation and characterization of exendin-4 from Heloderma suspectum venom. J Biol Chem 1992;267:7402. PubMed
Glucose: Frías JP et al. SURPASS-2. N Engl J Med 2021;385:503. doi
Diabetes prevention: le Roux CW et al. SCALE Obesity and Prediabetes, 3 years. Lancet 2017;389:1399. doi. Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392:958. doi. STEP 10 (semaglutide in prediabetes). PubMed
Weight: Pi-Sunyer X et al. SCALE. N Engl J Med 2015;373:11. doi. Wilding JPH et al. STEP 1. N Engl J Med 2021;384:989. doi. Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205. doi. ATTAIN-1 (orforglipron). N Engl J Med 2025. PubMed. Retatrutide TRIUMPH-1 topline, Eli Lilly, May 21, 2026, via The Pharmaceutical Journal. Orforglipron approval: Consultant360
Cardiovascular: Marso SP et al. LEADER. N Engl J Med 2016;375:311. doi. Marso SP et al. SUSTAIN-6. N Engl J Med 2016;375:1834. doi. Holman RR et al. EXSCEL. N Engl J Med 2017. PubMed. Gerstein HC et al. REWIND. Lancet 2019;394:121. doi. Lincoff AM et al. SELECT. N Engl J Med 2023;389:2221. doi. McGuire DK et al. SOUL. N Engl J Med 2025;392:2001. doi. Nicholls SJ et al. SURPASS-CVOT. N Engl J Med 2025;393:2409. doi. STRIDE (semaglutide in peripheral artery disease). Lancet 2025. PubMed
Heart failure: Kosiborod MN et al. STEP-HFpEF. N Engl J Med 2023;389:1069. doi. Packer M et al. SUMMIT. N Engl J Med 2025;392:427. doi
Kidney: Mann JFE et al. LEADER kidney outcomes. N Engl J Med 2017;377:839. doi. Tuttle KR et al. AWARD-7. Lancet Diabetes Endocrinol 2018;6:605. doi. Perkovic V et al. FLOW. N Engl J Med 2024;391:109. doi. Heerspink HJL et al. SMART. Nat Med 2025. doi. SELECT kidney outcomes. Nat Med 2024. PubMed. Meta-analysis in CKD. Am J Kidney Dis 2025. PubMed. Tuttle KR et al. REMODEL. Nat Med, October 2026. PubMed. KDIGO 2022 diabetes in CKD guideline. Kidney Int. ADA Standards of Care 2026, section 11. doi. Advanced CKD: Cardiovasc Diabetol 2023. doi. ESKD meta-analysis: Endocr Pract 2026. PubMed. Transplant meta-analysis: Clin Kidney J 2026. PMC. Transplant cohort: Lancet Diabetes Endocrinol 2025. PubMed. Review: Lancet 2026. PubMed
Liver: Sanyal AJ et al. ESSENCE. N Engl J Med 2025;392:2089. doi. Approval: AJMC
Sleep apnea: Malhotra A et al. SURMOUNT-OSA. N Engl J Med 2024;391:1193. doi
Knee and inflammation: Bliddal H et al. STEP 9. N Engl J Med 2024;391:1573. doi. Wong CK et al. Central GLP-1 receptor activation inhibits inflammation. Cell Metab 2024. PubMed. Retatrutide TRIUMPH-4 topline, December 2025, via The Pharmaceutical Journal
Brain and addiction: EVOKE and EVOKE+ results, CTAD 2025, via Alzheimer Europe. Semaglutide in alcohol use disorder. JAMA Psychiatry 2025. PubMed
Safety: FDA Drug Safety Communication on suicidal ideation, January 13, 2026. FDA. NAION: EMA PRAC, June 2025, via The Pharmaceutical Journal. SURPASS-CVOT adverse events via Pharmacy Times
After stopping, and who responds: Gasoyan H et al. Comparative effectiveness of obesity treatment strategies after semaglutide or tirzepatide, eClinicalMedicine 2026 (presented at Obesity Week), reported by Medscape, November 15, 2026. Aminian A et al. Bariatric surgery as a rescue strategy after semaglutide or tirzepatide. Ann Surg 2026. PubMed. Johnson H et al. (Voy) early response and cost effectiveness abstracts, Obesity Week 2026, reported by Medscape and Medscape; company authored, not peer reviewed
Eyes, cancer, fractures and mood: FDA Drug Safety Communication on NAION, November 9, 2026, via Pharmacy Times. Heberer K et al. NAION and semaglutide in US veterans. JAMA Ophthalmol 2026;144:259. PubMed. Natividade GR et al. Ocular adverse events with semaglutide. JAMA Ophthalmol 2025;143:759. PubMed. Ko A et al. Risk for cancer with GLP-1 receptor agonists and dual agonists. Ann Intern Med 2025. PubMed. Kasher Meron M et al. GLP-1 RAs and fragility fractures in older adults with type 2 diabetes. J Clin Endocrinol Metab 2026;111:1949. PubMed. Constantine E et al. Fracture risk in overweight or obese nondiabetic patients. J Am Acad Orthop Surg 2025. PubMed. Cathey JM et al. Upper extremity fragility fracture. Injury 2026. PubMed. Taipale H et al. GLP-1 RA use and worsening mental illness. Lancet Psychiatry 2026;13:327. PubMed. Overview: Cha AE, Wu D. The Washington Post, November 16, 2026
Muscle and bone: Langer HT et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Rep Med 2026;7:102665. PubMed. Hansen MS et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk. eClinicalMedicine 2024;72:102624. PubMed. Jensen SBK et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open 2024;7:e2416775. PubMed. Hamad CD et al. GLP-1 receptor agonists and fragility fracture risk in type 2 diabetes. JAMA Netw Open 2026;9:e2625141. PubMed. Clinical commentary: Dhami R. The GLP-1 muscle loss claim. Medscape, November 10, 2026
Compounded products: Mattingly TJ II, Duru EE, Maciejewski ML, Conti RM. Compounded GLP-1 dispensing patterns and vitamin B12 coformulation. JAMA, published online October 22, 2026. PubMed; summary via University of Utah Health. Chetty AK et al. Online prescribing of GLP-1 receptor agonists. JAMA 2026;336:428. PubMed. DiStefano MJ et al. Postshortage compounded GLP-1 RA market in 2 states. JAMA Health Forum 2026;7:e262207. PubMed. FDA adverse event count via AJMC
Persistence: Prime Therapeutics, J Manag Care Spec Pharm 2026;32:281. doi
Cost and coverage: November 2025 pricing agreement via AMCP. Medicare GLP-1 Bridge via KFF Health News